Results 251 to 260 of about 98,807 (272)

Gemcitabine resistance in pancreatic ductal adenocarcinoma

Drug Resistance Updates, 2015
Ziv Gil, Yoav Binenbaum, Shorook Na'Ara   +2 more
exaly  

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

Annals of Oncology, 2005
H L Kindler, J L Van Laethem, H Oettle
exaly  

Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer

Cell Metabolism, 2019
Jennifer Morton, Timothy Frankel, Daniel Kremer   +2 more
exaly  

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Lancet, The, 2017
David Cunningham, Gary Middleton, Alan Anthoney   +2 more
exaly  

A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study

British Journal of Cancer, 2012
H Isayama, Koike K, Hirano K
exaly  

Gemcitabine

Drugs, 2012
Stuart Noble, S Noble, Noble Stuart
exaly  

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

British Journal of Cancer, 2007
Yusuke Mizukami, Toshikatsu Okumura, Okumura T   +2 more
exaly  

Gemcitabine

Reactions Weekly, 2004
openaire   +1 more source

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

Lancet, The, 2008
Paul Bycott, Alejandro D Ricart, Sinil Kim   +2 more
exaly  

A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study

Annals of Oncology, 2015
Lorenza Rimassa, Angela Buonadonna, Michele Milella   +2 more
exaly